Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.

Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.

http://www.wikidata.org/entity/Q34019169

about

Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy Inducing Oncoprotein Degradation to Improve Targeted Cancer Therapy Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer BH4 domain of Bcl-2 as a novel target for cancer therapy Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer.Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview.Allosteric therapies for lung cancer.Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors.Modulation of Bax and mTOR for Cancer Therapeutics.Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview.

P2860

Q24337757-DAF4F75F-41FA-4165-8FD1-F157D2F52C09 Q26782145-90FAD085-BD89-425F-8D97-93535D04C3D0 Q35256618-5D41389D-8EB7-4555-87C2-4182A5D08E7F Q35463464-1F09F67A-65B7-431F-8CF2-BD54A7F1415E Q36940766-EF957BFC-34DF-49D4-90F8-8F01BDB052D4 Q37347532-CCE9E607-B390-4CE1-835A-CB68749D5A1A Q37721218-3889F7B8-BDA8-4FD1-9A76-34B73B78B758 Q37733727-B949DF89-9D32-4E28-ADA1-AF352ED179B1 Q37743107-BD3D4766-771C-4D99-813D-D52CE206F69A Q38268170-780AA7B9-CB6B-4E53-B4BB-37E75E51C458 Q38465098-51B632D1-5A41-4203-94A7-986089685B4A Q38515841-D8BBEB73-0572-4F96-984A-9DEC829DDBB4 Q39220897-C1B2C203-B022-4E8E-BD8B-C80DCA5EA617 Q46342083-CCD6A686-0A49-42FA-AB7E-018AD0A664B8 Q50662513-CFDC7269-52D4-47F6-8D89-4DFE87818C40 Q51122180-B6C840F7-3BB3-4770-8A7B-B87B3A497A69 Q51272851-44822CDC-E105-414B-81F2-C9BB745F16D1 Q55104021-387C4A79-815B-4032-9190-F17D26D59565

P2860

Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.

http://www.wikidata.org/entity/Q34019169

description

2013 nî lūn-bûn

@nan

2013 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մարտին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase II study of docetaxel in ...... ed non-small-cell lung cancer.

@ast

Phase II study of docetaxel in ...... ed non-small-cell lung cancer.

@en

Phase II study of docetaxel in ...... ed non-small-cell lung cancer.

@nl

type

label

Phase II study of docetaxel in ...... ed non-small-cell lung cancer.

@ast

Phase II study of docetaxel in ...... ed non-small-cell lung cancer.

@en

Phase II study of docetaxel in ...... ed non-small-cell lung cancer.

@nl

prefLabel

Phase II study of docetaxel in ...... ed non-small-cell lung cancer.

@ast

Phase II study of docetaxel in ...... ed non-small-cell lung cancer.

@en

Phase II study of docetaxel in ...... ed non-small-cell lung cancer.

@nl

P1433

Q34019169-9CE5A9B4-360F-4BEF-94B6-6036B936CEBD

P1476

Q34019169-5703A4F6-2602-424B-BA59-3C6D858FCC05

P2093

Q34019169-09D9627B-052A-4E66-AEEA-B4C76147A355

Q34019169-1363997D-8683-4AAD-801E-5065E67C3B58

Q34019169-19331486-6375-4EBD-8F21-5CAA128FD1CA

Q34019169-4B154D1A-BC3D-4F00-8EF1-AF18248DBEEA

Q34019169-68ED0722-A33F-451E-950C-5B0B435EC564

Q34019169-696A9726-E27B-4AC7-9957-564C240A967A

Q34019169-817979E3-8E6A-47EB-A681-D63B63646AE5

Q34019169-9E6421E6-A40C-4020-9CBC-B6B3466315DC

Q34019169-A39B2F1E-5591-40CA-A95C-BAC2874CE5B9

Q34019169-B64A619C-0875-4EB0-B789-156FC6511E6A

P2860

Q34019169-084E9202-E916-45AC-B890-C5C94A988808

Q34019169-24F5C928-DA3A-4C87-8C91-12B7E7F083AE

Q34019169-3EF4FDB2-4308-48F5-A8C9-AD361D3F5633

Q34019169-5100E961-3802-4F7F-9001-40226E2AB511

Q34019169-8000C24D-F10A-47BE-A5E8-43EC5094F6F2

Q34019169-94BBC2B9-B97D-4161-A30E-1D9852A7274A

Q34019169-96EB5559-585F-4291-8D42-0969AE14D48D

Q34019169-AD5EC4AC-00E5-467F-83D6-72E01AE39F20

Q34019169-E7DCA334-C62F-44FF-8FB7-1CFBDE631983

P304

Q34019169-F3F5F11E-2CA0-45CD-AB2F-5B96E1D2ECBE

P31

Q34019169-7C58511B-904E-4C56-96CA-8E82B3677909

P356

Q34019169-022D4E42-C352-4354-945E-2EFACD781149

P433

Q34019169-BC654CF3-C81B-4575-9DB1-CCC32439F431

P478

Q34019169-06E63510-6720-40BD-84CC-62C19E2DC67E

P50

Q34019169-019C7347-634F-45C8-8F48-C7F696E3029F

P577

Q34019169-5B69F638-06D4-4266-BA6F-46E2E8F2FF9D

P5875

Q34019169-294873F0-37C2-4CD8-864A-C2EB1F35C117

P698

Q34019169-4CC8BC0E-08B3-4F85-8002-187E9840731D

P932

Q34019169-853DCD78-C4FC-4199-8BC2-FC2CA1B89A1E

P356

JTO.0B013E318282709C

P1433

Journal of Thoracic Oncology

P1476

Phase II study of docetaxel in ...... ced non-small-cell lung cancer

@en

P2093

Anthony A Gal

http://www.w3.org/2001/XMLSchema#string

Carmen M Klass

http://www.w3.org/2001/XMLSchema#string

Dong M Shin

http://www.w3.org/2001/XMLSchema#string

Fadlo R Khuri

http://www.w3.org/2001/XMLSchema#string

Gabriel Sica

http://www.w3.org/2001/XMLSchema#string

Haian Fu

http://www.w3.org/2001/XMLSchema#string

Janakiraman Subramanian

http://www.w3.org/2001/XMLSchema#string

Madhusmita Behera

http://www.w3.org/2001/XMLSchema#string

Nabil F Saba

http://www.w3.org/2001/XMLSchema#string

R Donald Harvey

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.

Targeting mTOR signaling for lung cancer therapy.

RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid

Effects of the combination of RAD001 and docetaxel on breast cancer stem cells.

Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin.

P304

369-372

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/JTO.0B013E318282709C

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Taofeek K. Owonikoko

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235620634

http://www.w3.org/2001/XMLSchema#string

P698

23407561

http://www.w3.org/2001/XMLSchema#string

P932

4126230

http://www.w3.org/2001/XMLSchema#string